BIOPHARMA
By
Is AstraZeneca’s $20M AI Hub in Bengaluru the Catalyst for 20 New Medicines by 2030?
Key Highlights Strategic Investment to Scale AI-Driven InnovationAstraZeneca has inaugurated a state-of-the-art Global Hub in Bengaluru with an…
Can Lisata Therapeutics and GATC Health’s AI Breakthrough Redefine Drug Discovery and Tackle the Opioid Crisis in Just One Year?
Key Highlights AI-Powered Drug Discovery Moves Toward the Clinic with OUD FocusLisata Therapeutics and GATC Health have expanded…
Is Merck’s $10B Acquisition of Verona a Strategic Masterstroke to Offset Keytruda’s Patent Cliff and Dominate the $30B+ Respiratory Market?
Key Highlights Merck Secures Verona to Bridge Its Post-Keytruda Future Merck & Co. has taken a bold step…
Can Google DeepMind’s Isomorphic Labs Revolutionize Clinical Trials with AI-Designed Drugs Backed by $600M and AlphaFold Breakthrough?
Key Takeaways AI to Clinic: Isomorphic Labs Moves Beyond Design to Human TrialsIsomorphic Labs, the AI drug discovery…
Will Sanofi’s AI Ethics Revolution Trigger a $100 Billion Shift in Biopharma and Medtech? How the Company’s Transparency Drive is Reshaping Global Healthcare
Key Highlights: AI Ethics at Scale: Sanofi Sets Global Leadership StandardSanofi’s establishment of a dedicated AI Ethical Review…
Can IGC Pharma’s New AI Models Change Alzheimer’s Diagnosis and Drug Discovery for Millions?
New tools unveiled at AAIC 2025 aim to detect Alzheimer’s earlier and faster, even in low-resource settings Key…
